assay
≥95% (HPLC)
form
lyophilized
composition
Peptide Content, ≥75%
storage condition
protect from light
storage temp.
−20°C
General description
Amyloid plaques characteristic of the Alzheimer brain contain fibrils composed of amyloid β aggregates. Peptides, small organic molecules and nanoparticles can be used to bind or aggregate amyloid β (Aβ). They have been used as a strategy for the development of pharmaceutical approaches or agents to treat Alzheimer′s disease (AD). Short peptides containing the sequence KLVFF have been shown to bind specifically to the homologous region in Aβ and are used to prevent full length amyloid fibril formation.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Inhibition of amyloid-? aggregation in Alzheimer's disease.
Wang Q
Current Pharmaceutical Design (2014)
L O Tjernberg et al.
The Journal of biological chemistry, 272(19), 12601-12605 (1997-05-09)
We have previously shown that short peptides incorporating the sequence KLVFF can bind to the approximately 40amino acid residue Alzheimer amyloid beta-peptide (Abeta) and disrupt amyloid fibril formation (Tjernberg, L. O., Näslund, J., Lindqvist, F., Johansson, J., Karlström, A. R.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持